^
    1m
    ARTEMIDE-Lung03: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (clinicaltrials.gov)
    P3, N=878, Recruiting, AstraZeneca | Trial completion date: Mar 2030 --> Nov 2030 | Trial primary completion date: May 2029 --> Nov 2030
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • EGFR L861Q • ROS1 rearrangement • EGFR G719X • EGFR S768I • EGFR L858R + EGFR exon 19 deletion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)
    1m
    IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, Hospices Civils de Lyon | Recruiting --> Active, not recruiting | N=154 --> 27
    Enrollment closed • Enrollment change
    |
    5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154)
    1m
    Study of D3L-002 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, D3 Bio (Wuxi) Co., Ltd
    New P1 trial • First-in-human
    1m
    Tumor lymph node metastasis chip reveals that the NECTIN3-TIGIT axis promotes melanoma metastasis by enhancing treg cell function and inducing CD8+ T cell exhaustion. (PubMed, Cell Oncol (Dordr))
    The NECTIN3-TIGIT axis promotes melanoma lymph node metastasis by remodeling the immunosuppressive microenvironment. Combined blockade of NECTIN3-TIGIT and PD1 pathways represents a promising therapeutic strategy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • TRAF6 (TNF Receptor Associated Factor 6)
    |
    tiragolumab (RG6058)
    2ms
    STU-2022-1076: Domvanalimab and Zimberelimab in Advanced Liver Cancers (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, University of Texas Southwestern Medical Center | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date • Pan tumor
    |
    Yutuo (zimberelimab) • domvanalimab (AB154)
    2ms
    D9803C00001: A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cancers of the stomach and esophagus. (2024-519787-40-00)
    P2/3, N=126, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • Vyloy (zolbetuximab-clzb) • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    2ms
    GALAXIES Lung-301: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=88, Active, not recruiting, GlaxoSmithKline | Trial completion date: Feb 2027 --> Aug 2027 | Trial primary completion date: Feb 2027 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • belrestotug (EOS-448)
    2ms
    GALAXIES LUNG-201: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer (clinicaltrials.gov)
    P2, N=351, Active, not recruiting, GlaxoSmithKline | Trial completion date: Feb 2027 --> Dec 2027 | Trial primary completion date: Feb 2027 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    2ms
    SKYSCRAPER-15: A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (clinicaltrials.gov)
    P3, N=56, Terminated, Hoffmann-La Roche | Completed --> Terminated; Decision to terminate study was driven by results from preceding tiragolumab study (SKYSCRAPER-06;NCT04619797) & sponsor's strategic priorities, not due to safety risks or quality reasons for any of molecules/combinations investigated in this study.
    Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    2ms
    Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • tiragolumab (RG6058)
    2ms
    VELOCITY-Lung: Study of Novel Treatment Combinations in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=192, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154) • etrumadenant (AB928)
    3ms
    Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=126, Not yet recruiting, Sinocelltech Ltd.
    New P1/2 trial